ReviewDeutsches Arzteblatt international2023
Personalized Treatment for Patients With Lung Cancer.
Review in Deutsches Arzteblatt international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The Heidelberg Decision Aid for Patients With Lung Cancer (HELP)—Findings of a Randomized Controlled Trial.Deutsches Arzteblatt international · 2024Trial
- Review
- Prognostic impact of CEACAM5 in nonsquamous non-small cell lung cancer: a critical reappraisal driven by cut-off optimization.Translational lung cancer research · 2026Article
- Exploratory Analysis of HMGB1 Genetic Variants and Their Potential Association with Lung Cancer Susceptibility and Chemotherapy Response in a Chinese Population.Human heredity · 2026Article
- CLIC6 and ANLN: novel exosome-related prognostic markers and therapeutic targets in lung adenocarcinoma.Frontiers in immunology · 2026Article
- Concept and feasibility of privacy-preserving record linkage of cancer registry data and claims data in Germany: results from the DigiNet study on stage IV non-small cell lung cancer.Journal of cancer research and clinical oncology · 2025Article
- Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer.Cancers · 2025Article
- A Comprehensive Review on the Application of Artificial Intelligence for Predicting Postsurgical Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Using Computed Tomography, Positron Emission Tomography, and Clinical Data.Journal of medical radiation sciences · 2025Review
- The Impact of Artificial Intelligence on Lung Cancer Diagnosis and Personalized Treatment.International journal of molecular sciences · 2025Review
- Lung Cancer Therapy: The Role of Personalized Medicine.Cancers · 2025Review
- Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in theCancers · 2025Review
- Progress of tanshinone IIA against respiratory diseases: therapeutic targets and potential mechanisms.Frontiers in pharmacology · 2025Review
- Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review).Molecular and clinical oncology · 2024Review
- Radiomics and deep learning models to differentiate lung adenosquamous carcinoma: A multicenter trial.iScience · 2023Article
- Prediction of the Efficacy and Prognosis of Anlotinib in Lung Cancer Patients Using CT Radiomics.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the most common cause of death among all types of cancer in Germany, with an annual death rate of 45 000 patients. Over the past 15 years, innovations in diagnosis and treatment have prolonged the survival of patients with non-small-cell lung cancer in all tumor stages.
methodsThis review of the diagnosis and treatment of lung cancer is based on current national and international guidelines, and on prospective trials with the highest possible level of evidence that were retrieved by a selective search of the literature.
resultsImproved outcomes in patients with non-small-cell lung cancer (85% of new diagnoses) were achieved with the aid of precise diagnostic techniques, including functional imaging and endobronchial procedures for localized disease stage. Contemporary surgical and radio-oncological technologies reduce the morbidity and expand the boundaries of local therapy. Molecular pathology, including the assessment of predictive biomarkers, is an integral part of the diagnostic evaluation of non-small-cell lung cancer in all tumor stages; it enables stratified cytotoxic/molecularly targeted treatments and immunotherapies and improves patient-reported outcomes. The percentage of long-term survivors in the metastatic stage has doubled by the introduction of immunotherapy. In contrast, there has been no major improvement in the survival of patients with small-cell lung cancer (15% of new diagnoses).
conclusionIn addition to the implementation of lung cancer screening in high-risk populations, the further development and consistent implementation of personalized diagnosis and treatment in certified lung cancer centers can be expected to prolong survival and improve the patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.